Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
Phase: PHASE2
Conditions: Opioid-use Disorder
Sponsor: New York State Psychiatric Institute

Study: # 7812 entitled Lofexidine for management of opioid withdrawal with XR-NTX treatment 
 
PI: Frances R. Levin, MD 
NCT# NCT04056182 
 
Protocol created/approved 8-12-2019 
Data Analysis Plan created 8-15-2019